Correlation Between Vicore Pharma and Kancera AB

Can any of the company-specific risk be diversified away by investing in both Vicore Pharma and Kancera AB at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Vicore Pharma and Kancera AB into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Vicore Pharma Holding and Kancera AB, you can compare the effects of market volatilities on Vicore Pharma and Kancera AB and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Vicore Pharma with a short position of Kancera AB. Check out your portfolio center. Please also check ongoing floating volatility patterns of Vicore Pharma and Kancera AB.

Diversification Opportunities for Vicore Pharma and Kancera AB

-0.29

Correlation Coefficient

Vicore Pharma  Kancera AB

Very good diversification

The 3 months correlation between Vicore and Kancera is -0.29. Overlapping area represents the amount of risk that can be diversified away by holding Vicore Pharma Holding and Kancera AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Kancera AB and Vicore Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Vicore Pharma Holding are associated (or correlated) with Kancera AB. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Kancera AB has no effect on the direction of Vicore Pharma i.e., Vicore Pharma and Kancera AB go up and down completely randomly.

Pair Corralation between Vicore Pharma and Kancera AB

Assuming the 90 days trading horizon Vicore Pharma Holding is expected to generate 0.62 times more return on investment than Kancera AB. However, Vicore Pharma Holding is 1.6 times less risky than Kancera AB. It trades about 0.11 of its potential returns per unit of risk. Kancera AB is currently generating about 0.06 per unit of risk. If you would invest  633.00  in Vicore Pharma Holding on April 20, 2025 and sell it today you would earn a total of  146.00  from holding Vicore Pharma Holding or generate 23.06% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	98.36%
Values	Daily Returns

Vicore Pharma Holding  vs.  Kancera AB

Vicore Pharma Holding

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Vicore Pharma Holding are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, Vicore Pharma unveiled solid returns over the last few months and may actually be approaching a breakup point.

Kancera AB

Risk-Adjusted Performance

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Kancera AB are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Kancera AB unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Vicore Pharma and Kancera AB

The main advantage of trading using opposite Vicore Pharma and Kancera AB positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Vicore Pharma position performs unexpectedly, Kancera AB can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kancera AB will offset losses from the drop in Kancera AB's long position.

The idea behind Vicore Pharma Holding and Kancera AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.